Regenxbio reports Q4 EPS ($1.34), consensus ($1.27)

Reports Q4 revenue $22.2M, consensus $34M. “We started 2024 with amazing data from our AbbVie-partnered eye care programs and our treatments for Duchenne and Hunter syndrome. Our strategic pipeline prioritization at the end of 2023 created a sharpened focus for us and today we are rapidly advancing products through late-stage clinical trials. We believe this is the best way to support the creation of meaningful value,” said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. “We expect more important data readouts and milestones to be achieved across all programs and the initiation of new pivotal trials this year. 2024 will be a turning point in our journey to bring ground-breaking AAV Therapeutics to millions of patients.”